1. Clinical & Scientific Overview
Pemetrexed Disodium (TIP-MED-000556, Reference Code [ONC-07]) is classified under
Oncology & Antineoplastic Medicines as a Antimetabolite (Folate Antagonist) • Multi-Targeted Antifolate Antimetabolite.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Alimta (Eli Lilly and Company), Pemgem (Dr. Reddy's Laboratories), Pemetrex (Cipla Ltd)
Lyophilised Powder for IV Infusion: 100 mg vial, 500 mg vial
Oncology Specialisation & Cytotoxic Safety Protocol
Antimetabolite (Folate Antagonist)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: 500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle (contraindicated if CrCl <45 mL/min).
Signature Dose-Limiting Toxicities & Organ Monitoring: Severe myelosuppression, exfoliative skin rash, and mucositis if administered without mandatory Folic Acid and Vitamin B12 supplementation; nephrotoxicity and NSAID interaction (hold ibuprofen for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min).
Extravasation, Premedication & Safe Cytotoxic Handling: MANDATORY CO-MEDICATION PROTOCOL: Start Oral Folic Acid (400–1,000 mcg daily) at least 5–7 days before first Pemetrexed dose, give IM Vitamin B12 (1,000 mcg) 1 week before Day 1 and every 3 cycles (9 weeks), and give oral Dexamethasone 4 mg BD on Day -1, Day 1, and Day +1 to prevent rash.
3. Mechanism of Action & Pharmacodynamics
Polyglutamated intracellularly by folylpolyglutamate synthase (FPGS) to potently inhibit Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT), halting purine and pyrimidine de novo synthesis.
4. Therapeutic Indications & Evidence-Supported Uses
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC — ineffective in squamous NSCLC due to high TS expression)
- Malignant Pleural Mesothelioma (with Cisplatin)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle (contraindicated if CrCl <45 mL/min).
Administration & Meal Timing: 500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle (contraindicated if CrCl <45 mL/min).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Pemetrexed or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Severe myelosuppression, exfoliative skin rash, and mucositis if administered without mandatory Folic Acid and Vitamin B12 supplementation; nephrotoxicity and NSAID interaction (hold ibuprofen for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min).
8. Adverse Effects Profile
- Severe myelosuppression, exfoliative skin rash, and mucositis if administered without mandatory Folic Acid and Vitamin B12 supplementation; nephrotoxicity and NSAID interaction (hold ibuprofen for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min).
- Severe myelosuppression, exfoliative skin rash, and mucositis if administered without mandatory Folic Acid and Vitamin B12 supplementation; nephrotoxicity and NSAID interaction (hold ibuprofen for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Severe myelosuppression, exfoliative skin rash, and mucositis if administered without mandatory Folic Acid and Vitamin B12 supplementation; nephrotoxicity and NSAID interaction (hold ibuprofen for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min).
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: MANDATORY CO-MEDICATION PROTOCOL: Start Oral Folic Acid (400–1,000 mcg daily) at least 5–7 days before first Pemetrexed dose, give IM Vitamin B12 (1,000 mcg) 1 week before Day 1 and every 3 cycles (9 weeks), and give oral Dexamethasone 4 mg BD on Day -1, Day 1, and Day +1 to prevent rash.
Pharmacist Patient Counselling Points:
- MANDATORY CO-MEDICATION PROTOCOL: Start Oral Folic Acid (400–1,000 mcg daily) at least 5–7 days before first Pemetrexed dose, give IM Vitamin B12 (1,000 mcg) 1 week before Day 1 and every 3 cycles (9 weeks), and give oral Dexamethasone 4 mg BD on Day -1, Day 1, and Day +1 to prevent rash.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: MANDATORY CO-MEDICATION PROTOCOL: Start Oral Folic Acid (400–1,000 mcg daily) at least 5–7 days before first Pemetrexed dose, give IM Vitamin B12 (1,000 mcg) 1 week before Day 1 and every 3 cycles (9 weeks), and give oral Dexamethasone 4 mg BD on Day -1, Day 1, and Day +1 to prevent rash.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-06] Capecitabine — Antimetabolite (Fluoropyrimidine) • Oral Fluoropyrimidine Carbama
- [ONC-08] Epirubicin Hydrochloride — Anthracycline Cytotoxic Antibiotic • 4'-Epimer Anthracycline Topo
- [ONC-09] Daunorubicin Hydrochloride — Anthracycline Cytotoxic Antibiotic • Anthracycline Antileukaemic
- [ONC-10] Bleomycin Sulfate — Antitumour Antibiotic (G2/M Phase Specific) • Glycopeptide Radiom
